Abstract 4705
Background
Falls are one of the best safety indicators in hospitalized cancer patients. In 2013, a security group was created to promote a culture for patient safety, to prevent, register and analyses falls at 3 cancer centers of Catalan Institute of Oncology. WHO defined falls as the result of an incident that precipitates the patients down involuntarily, includes slipping, tripping and loss of body balance. A systematic review by Wildes (2015), risk factors for hospitalized cancer patients are different from the general patient. Objective: Identify predisposing factors to fall and define the profile of the hospitalized cancer patient with higher risk to fall.
Methods
A cross-sectional, multisite study. Inclusion: patients hospitalized in 3 centers during 2017. Data recruited as voluntary report of falls in a computerized system. Variables: socio-demographic, clinical and environmental factors.
Results
118 falls were reported; 48(40.68%) in Hospitalet; 36(30.51%) in Badalona and 34(28.81%) in Girona. Falls rate was 2.53‰, with lesion was 0.41‰ and severe lesion was 1.35% in one center. Nurses initially classified patients according to Stratify®: high risk 68(59.13%) and 47(40.87%) low-risk. A previous history of fall in last 6 months was for 18(15.25%). By diagnosis 39(33.06%) was lung and head-neck, hematologic 27(22.88%) and colorectal & GI 22(18.68%). The main cause of fall were loss of balance 31(26.50%), lack of strength/ weakness 26(22.22%) and slide 20(17.09%). Location at the hospital was 65 (55.08%) in oncology services, 29(24.58%) in hematology unit and 24(20.34%) in palliative care. Contributing factors was a risky medication 113(96.58%). Factors as being alone 69(58.47%), impairment of mobility 86(73.5%) and patient does not perceived any risk 101(89.38%).
Conclusions
Lung or head-neck neoplasia, medication of risk, mobility problems and the low perception of risk were the common factors resulting associated with a fall. Pautex 2008 indicated a similar rate than our for cancer patients. Room to improve for identification of the patient according to their risk is not enough but, some activities after assessment are needed. Stratify® does not fit properly to define factors related to cancer like anemia, fatigue, chemotherapy or pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract